- Home
- Companies
- faroe islands
- disease target
Show results for
Refine by
Disease Target Suppliers Serving Faroe Islands
69 companies found
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
based inHuesca, SPAIN
Vitassay develops and distributes reliable and certified solutions for the early detection of different pathogens which cause infectious diseases in humans. Our greatest asset is to offer a complete service for every customer to exceed their ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars ...
based inPaoli, NEW JERSEY (USA)
Beta Lifescience is a professional biotech company committed to providing premium quality life science research reagents worldwide across research and diagnostic markets. Our strong portfolio of recombinant proteins, viral antigens, antibodies, ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
based inRostock, GERMANY
Since 2006, CENTOGENE has helped physicians diagnose thousands of rare disease patients around the world. A quick and accurate diagnosis can end an odyssey of medical tests and visits to multiple medical specialists. It also helps physicians better ...
We work with partners to develop new disease models and new biomarkers of disease. We can also use our disease models to identify new drug targets and screen chemical compounds to ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of ...
based inCambridge, MASSACHUSETTS (USA)
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. ...
At Moderna, we are delivering on the promise of mRNA science to create a new generation of transformative medicines for ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Our efforts in haematology are currently focussed on non-malignant blood disorders including forms of anaemia. Our approach is to identify functional and developable lead molecules and quickly proceed to verified animal disease ...
based inBoston, MASSACHUSETTS (USA)
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — ...
based inBoston, MASSACHUSETTS (USA)
Neoclease is at the forefront of advancing gene editing technologies with a mission to transform healthcare by curing genetic diseases rather than just treating them. Utilizing a bespoke approach, the company develops tailored nucleases designed to ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Peptides are an increasingly important class of drug. As natural ligands to many targets, they can combine agonistic or antagonistic activity with low toxicity risk and can be applied to disease ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to ...
based inWellesley Heights, MASSACHUSETTS (USA)
Novel point-of-care diagnostics for earlier disease detection. SANO Diagnostics is developing a range of disposable, cost-effective point-of-care diagnostics to detect the early onset of inflammation in several disease states. We are a development ...
based inJena, GERMANY
Infectognostics – Research Campus for Innovative Infection Diagnostics and Infection Research. The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections. More than 30 partners from ...
based inHackney, UNITED KINGDOM
Lifebit has created a patented technology that enables researchers to run analyses on multiple, distributed datasets in-situ and avoid risky movement of highly-sensitive data. Lifebit empowers therapeutic leaders and pioneers in precision medicine ...
The velocity and volume of real world data (RWD) means it is impossible for humans alone to gain ultimate value from this type of information. Lifebit REAL uses Artificial Intelligence to make sense of RWD. Using REAL, you can unlock meaningful ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
In cancer, a balance between immune system effector and regulatory cells becomes disturbed. Regulatory T cells inhibit the activity of effector cells, including NK cells, a process known as immunosuppression. The PB003 (PureActivator) project ...
based inWendelsheim, GERMANY
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound ...
Certain proteins including α-synuclein can form disease-specific fibrillar amyloid aggregates. The misfolding/ aggregation pathway resulting in amyloid fibrils involves characteristic oligomer species which have been shown to ...